<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="203">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04347889</url>
  </required_header>
  <id_info>
    <org_study_id>IRB2020-00222</org_study_id>
    <nct_id>NCT04347889</nct_id>
  </id_info>
  <brief_title>Preventing COVID-19 in Healthcare Workers With HCQ: A RCT</brief_title>
  <official_title>Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19: A RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthcare workers (HCW) at risk of Covid-19 will have baseline serology for SARS-CoV-2 to
      see if they are already immune to Covid-19. HCW will get baseline assessment and if meeting
      inclusion criteria and no exclusion criteria they will be randomized in a 2:1 ratio to
      hydroxychloroquine or Vitamin C on a weekly basis for three months. Subjects will complete
      daily diary of symptoms and temperature, and will have repeat SARS-CoV-2 serology at 6 weeks
      and 3 months to determine seroconversion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthcare workers (HCW) at risk of Covid-19 will have baseline serology for SARS-CoV-2 to
      see if they are already immune to Covid-19. HCW will get baseline assessment and if meeting
      inclusion criteria and no exclusion criteria they will be randomized in a 2:1 ratio to
      hydroxychloroquine or Vitamin C on a weekly basis for three months. Subjects will complete
      daily diary of symptoms and temperature, and will have repeat SARS-CoV-2 serology at 6 weeks
      and 3 months to determine seroconversion.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open label, controlled, RCT</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcomes assessors will be masked to study assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>COVID-19 Seroconversion rate</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of healthcare worker who develop antibodies to SARS-CoV-2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Admission for Covid-19</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of study subjects who require admission to a hospital for Covid-19</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1212</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral loading dose of 800 mg followed by once weekly oral hydroxychloroquine 400 mg for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Vitamin C 1,000 mg daily for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Oral loading dose followed by once weekly dosing</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>Once daily vitamin C 1 gm</description>
    <arm_group_label>Vitamin C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthcare worker at risk of Covid-19

        Exclusion Criteria:

          -  Known hypersensitivity or allergic reactions to 4-aminoquinoline compounds or its
             ingredients.

          -  Current, or history of, ocular macular disease or retinal damage.

          -  Current, or history of, subnormal glomerular filtration.

          -  Current use of tamoxifen citrate.

          -  Current, or history of, cardiomyopathy, atrial, nodal, or ventricular arrhythmias,
             torsades de pointes, conduction disorders (bundle branch block/atrio-ventricular heart
             block) or biventricular hypertrophy.

          -  Subjects taking other drugs that have the potential to prolong QT interval if taken
             with HCQ.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stony Brook University</investigator_affiliation>
    <investigator_full_name>Adam Singer</investigator_full_name>
    <investigator_title>Professor and Vice Chairman for Research</investigator_title>
  </responsible_party>
  <keyword>covid-19</keyword>
  <keyword>healthcare workers</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>hydroxychloroquine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

